Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests.
Sign up today and learn more about Nucleix Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Nucleix Stock
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
Co-founder, VP Software & Analytics
VP Research & Co-founder
Chief Executive Officer
Member of Board of Directors
Dan J. Gelvan
Chief Financial Officer
W. Todd Myers